Hartaj Singh
Stock Analyst at Oppenheimer
(1.79)
# 3,204
Out of 5,182 analysts
106
Total ratings
48.42%
Success rate
-6.48%
Average return
Main Sectors:
Stocks Rated by Hartaj Singh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SRPT Sarepta Therapeutics | Upgrades: Outperform | $30 → $37 | $21.49 | +72.17% | 13 | Jul 29, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Outperform | $925 → $900 | $701.42 | +28.31% | 15 | Apr 29, 2025 | |
| GILD Gilead Sciences | Maintains: Outperform | $132 → $125 | $131.65 | -5.05% | 15 | Apr 25, 2025 | |
| VRTX Vertex Pharmaceuticals | Downgrades: Perform | n/a | $423.92 | - | 17 | Dec 19, 2024 | |
| SPRB Spruce Biosciences | Downgrades: Perform | n/a | $57.28 | - | 6 | Dec 11, 2024 | |
| UTHR United Therapeutics | Maintains: Outperform | $575 → $600 | $570.40 | +5.19% | 7 | Oct 31, 2024 | |
| MRNA Moderna | Downgrades: Perform | n/a | $45.37 | - | 8 | Sep 13, 2024 | |
| CLLS Cellectis | Maintains: Outperform | $11 → $10 | $3.97 | +151.89% | 5 | Jun 12, 2024 | |
| BMEA Biomea Fusion | Maintains: Outperform | $70 → $60 | $1.37 | +4,279.56% | 5 | May 30, 2024 | |
| GANX Gain Therapeutics | Maintains: Outperform | $9 | $1.88 | +378.72% | 4 | Apr 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 | $1.10 | +3,536.36% | 4 | Mar 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $22 | $14.50 | +51.72% | 1 | Jan 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $0.83 | - | 4 | Jul 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $650 | $4.93 | +13,084.58% | 1 | Nov 1, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $30 | $16.12 | +86.16% | 1 | Jan 26, 2018 |
Sarepta Therapeutics
Jul 29, 2025
Upgrades: Outperform
Price Target: $30 → $37
Current: $21.49
Upside: +72.17%
Regeneron Pharmaceuticals
Apr 29, 2025
Maintains: Outperform
Price Target: $925 → $900
Current: $701.42
Upside: +28.31%
Gilead Sciences
Apr 25, 2025
Maintains: Outperform
Price Target: $132 → $125
Current: $131.65
Upside: -5.05%
Vertex Pharmaceuticals
Dec 19, 2024
Downgrades: Perform
Price Target: n/a
Current: $423.92
Upside: -
Spruce Biosciences
Dec 11, 2024
Downgrades: Perform
Price Target: n/a
Current: $57.28
Upside: -
United Therapeutics
Oct 31, 2024
Maintains: Outperform
Price Target: $575 → $600
Current: $570.40
Upside: +5.19%
Moderna
Sep 13, 2024
Downgrades: Perform
Price Target: n/a
Current: $45.37
Upside: -
Cellectis
Jun 12, 2024
Maintains: Outperform
Price Target: $11 → $10
Current: $3.97
Upside: +151.89%
Biomea Fusion
May 30, 2024
Maintains: Outperform
Price Target: $70 → $60
Current: $1.37
Upside: +4,279.56%
Gain Therapeutics
Apr 23, 2024
Maintains: Outperform
Price Target: $9
Current: $1.88
Upside: +378.72%
Mar 8, 2024
Maintains: Outperform
Price Target: $40
Current: $1.10
Upside: +3,536.36%
Jan 5, 2024
Initiates: Outperform
Price Target: $22
Current: $14.50
Upside: +51.72%
Jul 5, 2023
Downgrades: Perform
Price Target: n/a
Current: $0.83
Upside: -
Nov 1, 2018
Initiates: Outperform
Price Target: $650
Current: $4.93
Upside: +13,084.58%
Jan 26, 2018
Maintains: Outperform
Price Target: $24 → $30
Current: $16.12
Upside: +86.16%